NasdaqCM · Biotechnology

Crescent Biopharma Inc (CBIO)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+78.4%

$30.60 average target

$17.15+0.92 (+5.7%)Latest market snapshot · Yahoo Finance

Market cap$637.0M

Cash$171.6M

Quarterly burn$19.5M

Pipeline assets5

Short float16.0%

Market expectations

Analyst Ratings & Price Targets

Data may be delayed

Street view at a glance

The average target implies 78.4% upsideTargets are estimates—not guarantees—and can change after company updates.

$30.60Average target

Wall Street consensus

Strong BuyBased on 5 analyst opinions

8ratings

Buy 7Hold 1Sell 0

Price-target range

$30.60

+78.4%

Low $27.00High $35.00

CurrentAverage

Bear case$27.00+57.4%

Base case$30.60+78.4%

Bull case$35.00+104.1%

Analyst coverage5published opinions

Bullish share88%buy recommendations

Target spread$8low-to-high dispersion

Consensus score1.41.0 is strongest

Recommendation mix

Current rating breakdown

8 tracked ratings

Company profile

About Crescent Biopharma Inc

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.